Luis G. Ortega Paz, M.D.

Luis G. Ortega Paz M.D.

Assistant Professor

Department: Department of Medicine
Business Phone: (904) 244-2060
Business Email: luis.ortegapaz@jax.ufl.edu
Appointments and Locations

About Luis G. Ortega Paz

Luis G. Ortega Paz, M.D., is an academic cardiologist. He was trained in cardiovascular diseases at the Cardiovascular Institute of the Hospital Clínic of Barcelona at the University of Barcelona. His primary research topics are clinical trials, antiplatelet therapy, platelet biology, acute coronary syndromes, and COVID-19-associated cardiovascular complications. He has published over 75 articles in indexed journals and five book chapters. He has been an investigator of several randomized clinical trials and prospective registries. He has presented lectures, oral communications, and Late-breaking clinical trials at international congresses. He obtained his Ph.D. degree in medicine and translational research program from the University of Barcelona. He is a professional member of the European Society of Cardiology, ESC thrombosis working group, and the European Interventional Cardiology Society. He is a member of the editorial team of EuroIntervention journal (section editor) and a peer reviewer for top cardiovascular medical journals.

Clinical Profile

Specialties
  • Cardiovascular Disease
Interests
  • Clinical Special Interests: antiplatelet therapy, bleeding avoidance strategies, acute coronary syndromes, metabolic syndromes, and COVID-19-associated cardiovascular complications.
  • Research Special Interests: Clinical trials, cardiovascular pharmacotherapy, acute coronary syndromes, bleeding avoidance strategies, lipid-lowering therapies, antidiabetic drugs, and COVID-19-associated cardiovascular complications.
Languages
  • Speaks English and Spanish

Publications

2024
Clopidogrel-Mediated P2Y12 Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD
JACC: Basic to Translational Science.9(7):865-876[DOI] 10.1016/j.jacbts.2024.03.003.[PMID] 39170956.
PubMed·Publisher's Site
2024
CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention
Journal of the American Heart Association.13(12):-[DOI] 10.1161/jaha.123.033791.[PMID] .
PubMed·Publisher's Site
2024
Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score
Journal of the American College of Cardiology.83(15):1370-1381[DOI] 10.1016/j.jacc.2024.02.015.[PMID] 38599713.
4 citations·PubMed·Publisher's Site
2024
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation after Percutaneous Coronary Intervention: The SWAP-AC–2 Study
JACC: Cardiovascular Interventions.():-[DOI] 10.1016/j.jcin.2024.03.027.[PMID] .
PubMed·Publisher's Site
2024
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study
Thrombosis and Haemostasis.124(03):263-273[DOI] 10.1055/a-2098-6639.[PMID] .
PubMed·Publisher's Site
2023
Oral P2Y12 inhibiting therapy in patients with acute coronary syndrome: finding the sweet spot
European Heart Journal.44(3):236-236[DOI] 10.1093/eurheartj/ehac601.[PMID] .
PubMed·Publisher's Site
2023
Sex Differences in 10-Year Outcomes After Percutaneous Coronary Intervention With Drug-Eluting Stents: Insights From the DECADE Cooperation
Circulation.147(7):575-585[DOI] 10.1161/circulationaha.122.062049.[PMID] .
PubMed·Publisher's Site
2023
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions.16(20):2528-2539[DOI] 10.1016/j.jcin.2023.08.009.[PMID] .
PubMed·Publisher's Site
2022
Impact of Diabetes on 10‐Year Outcomes Following ST‐Segment–Elevation Myocardial Infarction: Insights From the EXAMINATION‐EXTEND Trial
Journal of the American Heart Association.11(23):-[DOI] 10.1161/jaha.122.025885.[PMID] .
PubMed·Publisher's Site
2022
Mid-term effects of SARS-CoV-2 infection on cardiovascular outcomes
Medicina Clínica.158(1):41-42[DOI] 10.1016/j.medcli.2021.05.006.[PMID] 34147251.
1 citations·PubMed·Publisher's Site
2022
Mid-term effects of SARS-CoV-2 infection on cardiovascular outcomes
Medicina Clínica (English Edition).158(1):41-42[DOI] 10.1016/j.medcle.2021.05.008.[PMID] 35018305.
1 citations·PubMed·Publisher's Site
2022
P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention
Journal of Cardiovascular Development and Disease.9(10):340-[DOI] 10.3390/jcdd9100340.[PMID] 36286292.
3 citations·PubMed·Publisher's Site
2022
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
European Heart Journal - Cardiovascular Pharmacotherapy.8(7):677-686[DOI] 10.1093/ehjcvp/pvab070.[PMID] 34519777.
50 citations·PubMed·Publisher's Site
2021
Acute and Chronic Effects of COVID-19 on the Cardiovascular System
Journal of Cardiovascular Development and Disease.8(10):128-[DOI] 10.3390/jcdd8100128.[PMID] 34677197.
15 citations·PubMed·Publisher's Site
2021
Canakinumab for Secondary Prevention of Coronary Artery Disease
Future Cardiology.17(3):427-442[DOI] 10.2217/fca-2020-0211.[PMID] .
PubMed·Publisher's Site
2021
Coronary Endothelium‐Dependent Vasomotor Function After Drug‐Eluting Stent and Bioresorbable Scaffold Implantation
Journal of the American Heart Association.10(22):-[DOI] 10.1161/jaha.121.022123.[PMID] .
PubMed·Publisher's Site
2021
Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management
Journal of the American Heart Association.10(3):-[DOI] 10.1161/jaha.120.019650.[PMID] .
PubMed·Publisher's Site
2021
Myocardial Injury in COVID-19 Patients: Association with Inflammation, Coagulopathy and In-Hospital Prognosis
Journal of Clinical Medicine.10(10):2096-[DOI] 10.3390/jcm10102096.[PMID] 34068127.
16 citations·PubMed·Publisher's Site
2020
Very-late restenosis of a magnesium-based resorbable scaffold
European Heart Journal.41(27):2602-2602[DOI] 10.1093/eurheartj/ehaa391.[PMID] .
PubMed·Publisher's Site
2018
Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial
EuroIntervention.13(16):1939-1945[DOI] 10.4244/eij-d-17-00608.[PMID] .
PubMed·Publisher's Site
2018
Impact of PSP Technique on Clinical Outcomes Following Bioresorbable Scaffolds Implantation
Journal of Clinical Medicine.7(2):27-[DOI] 10.3390/jcm7020027.[PMID] 29415486.
11 citations·PubMed·Publisher's Site
2018
Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial)
The American Journal of Cardiology.121(9):1039-1045[DOI] 10.1016/j.amjcard.2018.01.015.[PMID] .
PubMed·Publisher's Site
2018
TIcaGrEloR and Absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization (TIGER-BVS trial): Rationale and study design
Catheterization and Cardiovascular Interventions.91(1):1-6[DOI] 10.1002/ccd.27196.[PMID] .
PubMed·Publisher's Site
2017
Bioresorbable scaffolds: should we stay simple or go complex?
Cardiovascular Diagnosis and Therapy.7(3):E7-E12[DOI] 10.21037/cdt.2017.01.07.[PMID] 28567366.
0 citations·PubMed·Publisher's Site
2017
Cardiac Magnetic Resonance as an Alternative to Endomyocardial Biopsy to Predict Recoverability of Left Ventricular Function in Methamphetamine- Associated Cardiomyopathy
JACC: Heart Failure.5(11):853-854[DOI] 10.1016/j.jchf.2017.08.009.[PMID] .
PubMed·Publisher's Site
2017
Complicaciones cardiacas graves por shabu: una droga emergente en Europa
Revista Española de Cardiología.70(11):1014-1016[DOI] 10.1016/j.recesp.2016.11.050.[PMID] .
PubMed·Publisher's Site
2017
Data from real-world registries: can it guide development of the bioresorbable scaffolds of tomorrow?
EuroIntervention.13(11):1259-1262[DOI] 10.4244/eijv13i11a197.[PMID] .
PubMed·Publisher's Site
2017
Endothelial function impairment in STEMI patients with out-of-hospital cardiac arrest under therapeutic hypothermia treatment
International Journal of Cardiology.232():70-75[DOI] 10.1016/j.ijcard.2017.01.050.[PMID] .
PubMed·Publisher's Site
2017
Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST–Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation
The American Journal of Cardiology.120(9):1460-1466[DOI] 10.1016/j.amjcard.2017.07.040.[PMID] .
PubMed·Publisher's Site
2017
Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry
Catheterization and Cardiovascular Interventions.89(5):812-818[DOI] 10.1002/ccd.26674.[PMID] .
PubMed·Publisher's Site
2017
Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the five-year follow-up of the EXAMINATION trial
EuroIntervention.13(5):e557-e563[DOI] 10.4244/eij-d-16-00512.[PMID] .
PubMed·Publisher's Site
2017
miRNA Update: A Review Focus on Clinical Implications of miRNA in Vascular Remodeling
AIMS Medical Science.4(1):99-112[DOI] 10.3934/medsci.2017.1.99.[PMID] .
PubMed·Publisher's Site
2017
Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score
EuroIntervention.12(17):2110-2117[DOI] 10.4244/eij-d-16-00974.[PMID] .
PubMed·Publisher's Site
2017
Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial
American Heart Journal.189():128-136[DOI] 10.1016/j.ahj.2017.03.017.[PMID] .
PubMed·Publisher's Site
2017
Serial optical coherence tomography assessment of malapposed struts after everolimus-eluting stent implantation. A subanalysis from the HEAL-EES study
Cardiovascular Revascularization Medicine.18(1):47-52[DOI] 10.1016/j.carrev.2016.08.010.[PMID] .
PubMed·Publisher's Site
2016
ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison
International Journal of Cardiology.214():483-484[DOI] 10.1016/j.ijcard.2016.04.016.[PMID] .
PubMed·Publisher's Site
2016
Bioresorbable vascular scaffolds technology: current use and future developments
Medical Devices: Evidence and Research.Volume 9():185-198[DOI] 10.2147/mder.s90461.[PMID] .
PubMed·Publisher's Site
2016
Could Plaque Composition-Related Endothelial Dysfunction Predict Poor Prognosis in Coronary Vasospastic Angina?
Journal of the American College of Cardiology.67(15):1867-[DOI] 10.1016/j.jacc.2015.12.070.[PMID] .
PubMed·Publisher's Site
2016
Five-Year Optical Coherence Tomography in Patients With ST-Segment–Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents
Circulation: Cardiovascular Interventions.9(10):-[DOI] 10.1161/circinterventions.116.003670.[PMID] .
PubMed·Publisher's Site
2016
Lesión miocárdica en consumidor de shabú: patrón multifocal de realce tardío de gadolinio
Medicina Clínica.147(12):570-[DOI] 10.1016/j.medcli.2016.07.034.[PMID] .
PubMed·Publisher's Site
2016
Optical coherence tomography: A pathway from research to clinical practice
Cardiovascular Revascularization Medicine.17(2):71-73[DOI] 10.1016/j.carrev.2016.02.009.[PMID] .
PubMed·Publisher's Site
2016
TCT-404 ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-year results from a propensity score matched comparison
Journal of the American College of Cardiology.68(18):B164-[DOI] 10.1016/j.jacc.2016.09.539.[PMID] .
PubMed·Publisher's Site
2016
TCT-419 Usefulness of a scoring system for predicting adverse cardiovascular events in patients undergoing everolimus-eluting bioresorbable scaffolds implantation: the PSP score
Journal of the American College of Cardiology.68(18):B169-B170[DOI] 10.1016/j.jacc.2016.09.554.[PMID] .
PubMed·Publisher's Site
2015
Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks
Advances in Interventional Cardiology.3(3):161-169[DOI] 10.5114/pwki.2015.54006.[PMID] 26677353.
10 citations·PubMed·Publisher's Site
2015
Letter by Ortega-Paz et al Regarding Article, “East Asian Variant of Aldehyde Dehydrogenase 2 Is Associated With Coronary Spastic Angina: Possible Roles of Reactive Aldehydes and Implications of Alcohol Flushing Syndrome”
Circulation.132(24):-[DOI] 10.1161/circulationaha.115.018218.[PMID] .
PubMed·Publisher's Site
2015
Percutaneous Transcatheter Aortic Valve Implantation: A Review Focus on Outcomes and Safety
AIMS Medical Science.2(3):200-221[DOI] 10.3934/medsci.2015.3.200.[PMID] .
PubMed·Publisher's Site
2012
Pre-eclampsia/eclampsia and hepatic rupture
International Journal of Gynecology & Obstetrics.118(3):186-189[DOI] 10.1016/j.ijgo.2012.03.042.[PMID] .
PubMed·Publisher's Site
2011
Retinal detachment in association with pre-eclampsia, eclampsia, and HELLP syndrome
International Journal of Gynecology & Obstetrics.114(3):223-225[DOI] 10.1016/j.ijgo.2011.04.003.[PMID] .
PubMed·Publisher's Site

Office Information

Academic Office
Ambulatory Care Center, 5th Floor
655 West 8th Street
Jacksonville, FL 32209
(904) 244-2060
 luis.ortegapaz@jax.ufl.edu
Medical Secretary
 Monica George
(904) 244-2060
monica.george@jax.ufl.edu

Education

Medical Degree
2010 · Universidad de Panama, Panama City, Panama
Cardiovascular Disease Fellowship
2021 · University of Barcelona, Barcelona, Spain